share_log

Several Dynavax Technologies Insiders Sell Shares Sending Potential Negative Signal

Several Dynavax Technologies Insiders Sell Shares Sending Potential Negative Signal

多名德納維製藥內部人士賣出股票,可能傳遞出負面信號。
Simply Wall St ·  08/08 18:38

A number of Dynavax Technologies Corporation (NASDAQ:DVAX) insiders sold their shares in the last year, which may have raised concerns among investors. When evaluating insider transactions, knowing whether insiders are buying is usually more beneficial than knowing whether they are selling, as the latter can be open to many interpretations. However, when multiple insiders sell stock over a specific duration, shareholders should take notice as that could possibly be a red flag.

在過去的一年中,德納維製藥公司(NASDAQ:DVAX)的許多內部人士出售了其股票,這可能引起了投資者的擔憂。在評估內部交易時,通常了解內部人員是否在購買股票比了解他們是否在出售股票更有益,因爲後者可能有許多解讀。然而,當多名內部人員在特定期間內出售股票時,股東們應該注意,因爲這可能是一個警示信號。

Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.

雖然我們不認爲股東應該簡單地跟隨內部交易,但完全忽略內部交易將是愚蠢的。

Dynavax Technologies Insider Transactions Over The Last Year

在過去的一年中,德納維製藥公司內部交易

In the last twelve months, the biggest single sale by an insider was when the Chief Accounting Officer & Controller, Justin Burgess, sold US$172k worth of shares at a price of US$12.78 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The good news is that this large sale was at well above current price of US$10.75. So it may not shed much light on insider confidence at current levels.

在過去的十二個月中,首席會計官兼電機控制器賈斯汀·伯吉斯(Justin Burgess)以每股12.78美元的價格出售價值17.2萬美元的股票,其中最大的單筆內部交易是賈斯汀·伯吉斯(Justin Burgess)賣出股票。我們通常不喜歡看到內部人員出售股票,但銷售價格越低,我們就越擔心。好消息是,這次大規模出售價格遠高於當前10.75美元的價格。因此它可能對當前水平的內部人員信心沒有什麼幫助。

Insiders in Dynavax Technologies didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

德納維製藥公司內部人士在過去的一年中沒有購買任何股票。您可以查看過去12個月內(按公司和個人)的內部交易的視覺呈現如下。如果您單擊圖表,則可以查看所有單個交易,包括股票價格,個人和日期!

big
NasdaqGS:DVAX Insider Trading Volume August 8th 2024
NasdaqGS:DVAX內部交易成交量2024年8月8日

I will like Dynavax Technologies better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

如果有一些大規模內部人員買入,我將更喜歡德納維製藥公司。等待時,請查看這個免費的低估且小盤股票列表,其中包括相當多的最近內部買入。

Dynavax Technologies Insiders Are Selling The Stock

德納維製藥公司內部人員正在出售股票

The last three months saw some Dynavax Technologies insider selling. Independent Director Francis Cano divested only US$43k worth of shares in that time. It's not great to see insider selling, nor the lack of recent buyers. But the volume sold is so low that it really doesn't bother us.

過去三個月中,德納維製藥公司內部人員出售了一些股票。獨立董事弗朗西斯·卡諾(Francis Cano)在那段時間內僅賣出價值4.3萬美元的股票。看到內部人員出售股票或近期無買家並不是好事。但出售的數量很少,所以這並沒有很困擾我們。

Insider Ownership

內部人員持股情況

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Based on our data, Dynavax Technologies insiders have about 0.3% of the stock, worth approximately US$4.0m. I generally like to see higher levels of ownership.

另一種測試一家公司領導人和其他股東的協作程度的方法是查看他們擁有的股票數量。我們通常希望看到相當高水平的內部所有權。根據我們的數據,德納維製藥公司內部人士持有大約0.3%的股票,價值約400萬美元。我通常希望看到更高的所有權水平。

So What Do The Dynavax Technologies Insider Transactions Indicate?

那麼德納維製藥公司內部交易到底意味着什麼?

We did not see any insider buying in the last three months, but we did see selling. But given the selling was modest, we're not worried. Recent insider selling makes us a little nervous, in light of the broader picture of Dynavax Technologies insider transactions. And usually insiders own more stock in the company, according to our data. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. While conducting our analysis, we found that Dynavax Technologies has 1 warning sign and it would be unwise to ignore this.

我們沒有看到過去三個月內的內部購買,但我們確實看到了出售。但考慮到這次銷售規模較小,我們並不擔心。最近的內部銷售讓我們有點緊張,考慮到德納維製藥公司內部交易的整體情況。根據我們的數據,內部人員通常會在公司擁有更多的股票。因此,這些內部交易可以幫助我們建立關於股票的論點,但了解這家公司面臨的風險也很有價值。在進行分析的過程中,我們發現德納維製藥公司存在一個警示信號,忽視它將是不明智的。

Of course Dynavax Technologies may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

當然,德納維製藥公司可能不是最好的股票購買選擇。因此,您可能希望查看這個高質量公司的免費集合。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論